~6 spots leftby May 2026

Bioinductive Implant for Tennis Elbow

NA
JK
Overseen ByJohnny Kasto, MD
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Recruiting
Sponsor: Henry Ford Health System
Disqualifiers: Previous elbow surgery
No Placebo Group
Prior Safety Data
Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

The investigators are testing the efficacy of a new, FDA-approved bioinductive patch in lateral epicondylitis (tennis elbow) patients. A bioinductive patch is an implant that may foster tendon regrowth and healing following surgery. Patients will be randomize into one of two groups: control and investigational. Patients in the "control group" will receive the normal surgery for patients who do not respond to physical therapy, lifestyle changes, and anti-inflammatory treatment. Patients in the "experimental group" will receive the same surgical treatment, with the addition of the bioinductive patch. This patch will be implanted during surgery. Then, using a combination of ultrasound studies and other measures, the investigators will assess how well the patch works compared to surgery alone.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Smith & Nephew Bioinductive Implant for tennis elbow?

The use of bio-inductive implants, like the Smith & Nephew Bioinductive Implant, has shown promise in other conditions such as rotator cuff repair, where they help in new tissue formation. This suggests potential benefits for tissue healing in tennis elbow as well.12345

Is the Bioinductive Implant safe for use in humans?

Research shows that bioinductive implants, like the resorbable bovine collagen implant, have been safely used in humans for conditions like rotator cuff tears and tendinopathies, with studies reporting positive safety outcomes.34678

How does the Smith & Nephew Bioinductive Implant treatment for tennis elbow differ from other treatments?

The Smith & Nephew Bioinductive Implant is unique because it uses a bioinductive material to encourage the body's natural healing process, potentially offering a less invasive alternative to traditional surgical options like elbow replacement, which involves replacing joint surfaces with metal and plastic components.910111213

Research Team

SJ

Stephanie J Muh, MD

Principal Investigator

Henry Ford Health System

Eligibility Criteria

This trial is for individuals with tennis elbow that hasn't improved after physical therapy, lifestyle changes, and anti-inflammatory treatments. It's not open to those who've had previous surgery on the affected elbow.

Inclusion Criteria

My tennis elbow didn't improve with standard treatments like physical therapy.

Exclusion Criteria

I have had surgery on my affected elbow before.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo surgical treatment with or without the bioinductive patch implant

Immediate (surgery)
1 visit (in-person, surgery)

Follow-up

Participants are monitored for safety and effectiveness after treatment using ultrasound and other measures

1 year
Multiple visits (in-person) including preoperative and 6 months postoperative

Treatment Details

Interventions

  • Smith & Nephew Bioinductive Implant (Bioinductive Implant)
Trial OverviewThe study compares traditional surgery for tennis elbow against the same surgery plus a new FDA-approved bioinductive patch designed to promote tendon healing. Participants will be randomly assigned to one of these two groups.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment3 Interventions
Identical surgical treatment plus Smith \& Nephew bio-inductive patch implant. Ultrasounds preoperatively and 6 months postoperatively.
Group II: ControlActive Control2 Interventions
Surgical treatment alone, consisting of tendon debridement and repair. Ultrasounds preoperatively and 6 months postoperatively.

Smith & Nephew Bioinductive Implant is already approved in Japan for the following indications:

🇯🇵
Approved in Japan as REGENETEN Bioinductive Implant for:
  • Management and protection of tendon injuries in which there has been no substantial loss of tendon tissue

Find a Clinic Near You

Who Is Running the Clinical Trial?

Henry Ford Health System

Lead Sponsor

Trials
334
Recruited
2,197,000+

Smith & Nephew, Inc.

Industry Sponsor

Trials
176
Recruited
23,500+
Dr. Maria Berkman profile image

Dr. Maria Berkman

Smith & Nephew, Inc.

Chief Medical Officer since 2023

MD from Harvard Medical School

Dr. Deepak Nath profile image

Dr. Deepak Nath

Smith & Nephew, Inc.

Chief Executive Officer since 2022

PhD in Theoretical Mechanics, University of California, Berkeley

Findings from Research

In a study of 52 patients with chronic lateral epicondylitis, both autologous conditioned plasma (ACP) injections and low-level laser therapy resulted in significant clinical improvements, with 63.5% of patients achieving successful treatment outcomes after one year.
ACP therapy is highlighted as a promising and easy-to-apply alternative treatment option for lateral epicondylitis, showing comparable efficacy to laser therapy in improving pain and function.
Autologous proliferative therapies in recalcitrant lateral epicondylitis.Tetschke, E., Rudolf, M., Lohmann, CH., et al.[2016]
In a study of 126 patients with resistant lateral tennis elbow, a quick surgical technique involving the desinsertion of epicondylar muscles led to successful outcomes in 112 cases, indicating a high efficacy of the procedure.
The best results were observed in younger patients and athletes with early-stage lesions, suggesting that early intervention may improve surgical outcomes.
[Surgical treatment of refractory tennis elbow. Apropos of 126 cases].Saillant, G., Edouard, B., Benazet, JP., et al.[2009]
A novel technique using a bio-inductive implant is proposed for treating insertional patellar tendinopathies and symptomatic partial tears, which could offer a new option for athletes suffering from this condition.
Most current treatments for patellar tendinopathies are non-surgical, and when surgery is needed, traditional methods involve open debridement or tendon repair, highlighting the potential benefits of this innovative approach.
Treatment of an Insertional High Grade Partial Patellar Tendon Tear Utilizing a Bio-Inductive Implant.Mc Millan, S., Faoao, DO., Ford, E.[2020]

References

Autologous proliferative therapies in recalcitrant lateral epicondylitis. [2016]
[Surgical treatment of refractory tennis elbow. Apropos of 126 cases]. [2009]
Treatment of an Insertional High Grade Partial Patellar Tendon Tear Utilizing a Bio-Inductive Implant. [2020]
Arthroscopic Rotator Cuff Repair Technique Using a Bio-Composite Scaffold for Tissue Augmentation. [2022]
Allogeneic platelet-derived growth factors local injection in treatment of tennis elbow: a prospective randomized controlled study. [2022]
Full-Thickness Rotator Cuff Tears Can Be Safely Treated With a Resorbable Bioinductive Bovine Collagen Implant: One-Year Results of a Prospective, Multicenter Registry. [2022]
Patient-Reported Outcomes After Use of a Bioabsorbable Collagen Implant to Treat Partial and Full-Thickness Rotator Cuff Tears. [2020]
Bioinductive Collagen Implant Augmentation for the Repair of Chronic Lower Extremity Tendinopathies: A Report of Two Cases. [2021]
[Total elbow arthroplasty]. [2014]
Early results of the Acclaim elbow replacement. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Minimally constrained elbow implant arthroplasty: the discovery elbow system. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
Imaging of elbow replacement arthroplasty. [2022]
13.United Statespubmed.ncbi.nlm.nih.gov
Experience with the Coonrad-Morrey total elbow arthroplasty: 78 consecutive total elbow arthroplasties reviewed with an average 5 years of follow-up. [2022]